Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + cemdisiran in PNH patients inadequately controlled on C5 inhibitors
KCT0010985Phase 3Not yet recruiting
- Sponsor
- Parexel
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pozelimab, cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Parexel. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on KCT0010985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010985.